Extensive funding and experiments…the latest developments in producing a vaccine against the Ebola virus
International organizations announced the intensification of efforts to take immediate action to confront the Ebola in the Republic of Democratic Republic of the Congo and Uganda, quickly developing a vaccine against the strain "Bundibgio" The new epidemic, which has caused about 250 deaths and more than 1,100 infections recorded so far, has pushed scientists and international health organizations into a race against the clock to find a vaccine that can be produced quickly, then tested in clinical trials in the affected African region.
There is currently no approved vaccine or treatment for the strain. "Bundibgio"
The vaccine most likely to succeed
The World Health Organization indicated on Saturday that the vaccine most likely to be successful is a vaccine. "R-VSV" The single-dose vaccine developed by the International AIDS Vaccine Initiative, and its development is based on the same basis as the development of a vaccine "Ervibo" Licensed against the most common Zaire strain of Ebola virus.
The organization announced "Ayafi" The non-profit on Monday concluded an agreement with the University of Texas Medical Branch to develop this vaccine.
Virologist Thomas Geisbert, who supervised the development of the vaccine, said "Ervibo" And producing a similar vaccine targeting the current strain. Experiments conducted on monkeys in 2013 showed effective protection against the strain. "Bundibegyo".
However "The project remained at a standstill" For more than a decade due to a lack of interest, especially from pharmaceutical groups, he explained at the time.
The number of people suspected of having fever reached
For more:
The World Health Organization estimated that it would likely take between seven and nine months before a vaccine became available. "R-VSV" Anti-dynasty "Bondeggio" Ready to be tested on humans in a clinical trial.
The Coalition for Epidemic Preparedness Innovations also announced on Monday funding to accelerate the development of three vaccines against the strain. "Bundibgio"among them "R-VSV"
The Director-General of the World Health Organization, Tedros Adhanom Ghebreyesus, described this step as an important advance.
Developing a vaccine. "AstraZeneca"
The funding contributes to the development of another vaccine at the University of Oxford, which also worked on a vaccine "AstraZeneca" Anti-Covid.
This vaccine, which will be produced by the world’s largest vaccine manufacturer, the Serum Institute of India, may become available for clinical trials within two to three months, according to the World Health Organization.
The third vaccine candidate to receive funding from… "Coalition for Epidemic Preparedness Innovations"Developed by the American pharmaceutical giant "Moderna"It uses messenger RNA technology.
- For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and Twitter
